Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage
pharmaceutical company commercializing potential best in class oncology
and CNS therapeutics, today announced that the European Patent Office
has granted European patent No. 2099765 to Rexahn, entitled "5,
6, or 7-Substituted-3-arylisoquinolinamine derivatives as antitumor
This patent covers several new isoquinolinamine compounds and their
pharmaceutical composition and method for producing an anti-tumor
effect. Studies show that isoquinolinamine compounds have potent
anti-tumor properties in several cancer cell lines, such as breast,
prostate, colon, ovary, kidney, pancreas, glioblastoma and melanoma.
This class of isoquinolinamine compounds significantly inhibited the
growth of paclitaxel (Taxol®) resistant HCT-15 human
colorectal cancer cells and tumor growth in an in vivo model of
nude mice injected with paclitaxel-resistant HCT-15 human colorectal
Rexahn has been awarded patents for isoquinolinamine compounds in the
United States, Mexico, China and now Europe.
"This patent coverage in Europe supports Rexahn's goal of accelerated
development of this exciting new class of anti-cancer compounds," said
Rick Soni, President of Rexahn.
Rexahn Pharmaceuticals, Inc.